Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arena Pharmaceuticals Inc. ARNA

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimm...


NDAQ:ARNA - Post by User

Bullboard Posts
Post by MiamiGenton Oct 24, 2013 9:02am
456 Views
Post# 21844407

Arena (ARNA) is a Winner For Investors

Arena (ARNA) is a Winner For Investors

Arena (ARNA) is a Winner For Investors

Arena (ARNA) is a winner for investors

...and currently at a very attractive price!

Arena's mature, straight forward CEO told us it was going to take time.
Eisai is a capable marketer of pharmaceuticals. It paid Arena a ton of money for the right to sell Belviq in North and most of South America. It will move mountains to get that back and earn a profit. It has a well honed marketing plan. They are educating the Doctors before the TV advertising can begin.
We are hearing better than expected reports on the efficacy of Belviq, albeit from ARNA shareholders so must be tempered some.
Our only close competitor has one hand tied behind its back and is troubled.
Gaining customers for Belviq and repeat orders is an accretive process. In time, the miracle of numbers will be evident
Arena has a promising pipeline, too.

MG
https://stockcharts.com/h-sc/ui?s=ARNA


Bullboard Posts